Skip to main content
SpringerLink
Log in

Pneumococcal vaccine cost effective in older adults

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2016 International dollars

  2. 2016 International dollars

Reference

  • Nishikawa AM, et al. Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60years of age or older. Vaccine : 2 Apr 2018. Available from: URL: http://doi.org/10.1016/j.vaccine.2018.03.070

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pneumococcal vaccine cost effective in older adults. PharmacoEcon Outcomes News 801, 28 (2018). https://doi.org/10.1007/s40274-018-4883-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4883-5

Search

Navigation